ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質、抗体、アッセイキット

タンパク質カタログ

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

サプライヤー
TargteMol
カタログNo.
TMPY-05208
製品名称
PD-L1 Protein, Human, Recombinant
タンパク質名
PD-L1
Species
Human
HOST
HEK293 Cells
100μg: -
お問い合わせ

Overview

Synonyms CD274 molecule, PDCD1L1, PD-L1, PDL1, PDCD1LG1, B7H1, B7-H, B7-H1
Characteristics Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Endotoxin Level < 1.0 EU/μg of the protein as determined by the LAL method.
Purity 95.90%
Description PD-L1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 25.2 kDa and the accession number is Q9NZQ7-1.
Reference Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.,Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.,Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.,Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.,Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
URL https://www.targetmol.com/recombinant-protein/pd_l1_protein_human_recombinant_ecd_hplc_verified

お問い合わせリスト(-)

お問い合わせフォーム